Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with nivolumab versus placebo in all randomized patients (HR 0.66, 95% CI 0.53-0.81) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback